Health Condition 1: null- Post menopausal Osteoporosis
Conditions
Interventions
Intervention1: Group 1: 2 mg zoledronic acid will be given once at baseline intravenously over 15 minutes and bone mineral density will be measured at 12 months
Control Intervention1: Group 2: 4 mg zo
Sponsors
JIPMER Intramural fund
Eligibility
Inclusion criteria
Inclusion criteria: Post menopausal osteoporosis with T score at lumbar spine of -2.5 or less
Exclusion criteria
Exclusion criteria: 1.Evidence suggestive of secondary osteoporosis: a)parathyroid disorders, hyperthyroidism, Cushingâ??s disease, etc. b)drug history suggestive of usage of medications such as corticosteroids (either intravenous, oral or inhaled), anti-convulsants, anti-tubercular and other drugs causing osteoporosis; 2.Serum 25 (OH) D level less than 15 ng/ml. 3.Clinical and/or biochemical evidence of renal, liver or cardiac disease. 4.Autoimmune diseases such as rheumatoid arthritis, multiple sclerosis or SLE. 5.Systemic illness such AIDS/HIV. 6.Hematological disorders such as thalassemia, sickle cell disease, multiple myeloma, leukemia, lymphoma, etc. 7.History of cancer; 8.Previous or current treatment with bisphosphonates, teriparatide or any other medication known to affect skeleton.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density at lumbar spineTimepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density at total hip, femoral neck and distal forearmTimepoint: 12 months;Bone turnover markersTimepoint: 12 months;Incidence of new fracturesTimepoint: 12 months | — |
Countries
India
Contacts
Public ContactDr Sadish Kumar Kamalanathan
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed